Literature DB >> 20848508

Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy.

Corey A Siegel1.   

Abstract

Patients with inflammatory bowel disease are commonly treated with immunomodulators and biologic therapy. These treatments can be very effective, but are associated with risks of adverse events that need to be discussed with patients. Effectively communicating risks of therapy can be challenging based on time constraints, misinformation available on the Internet and from others, and the lack of tools to efficiently share accurate data with patients and their families. Providers need to acknowledge the emotional aspect involved in the perception of risk, and be aware of mistakes that can easily be made in communicating with patients. Tools are available to make medical data easier to understand, and these techniques have been adapted for patients with inflammatory bowel disease. By more clearly communicating with patients, we can ensure that they are making informed medical decisions that fit with their personal preferences for treatment.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20848508      PMCID: PMC3037287          DOI: 10.1002/ibd.21305

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  27 in total

Review 1.  How to do without steroids in inflammatory bowel disease.

Authors:  D H Present
Journal:  Inflamm Bowel Dis       Date:  2000-02       Impact factor: 5.325

2.  Numeracy and the medical student's ability to interpret data.

Authors:  Stacey L Sheridan; Michael Pignone
Journal:  Eff Clin Pract       Date:  2002 Jan-Feb

3.  Perception of risk.

Authors:  P Slovic
Journal:  Science       Date:  1987-04-17       Impact factor: 47.728

4.  Intestinal cancer risk and mortality in patients with Crohn's disease.

Authors:  P Munkholm; E Langholz; M Davidsen; V Binder
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

5.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

Authors:  D H Present; S J Meltzer; M P Krumholz; A Wolke; B I Korelitz
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Frequency or probability? A qualitative study of risk communication formats used in health care.

Authors:  M M Schapira; A B Nattinger; C A McHorney
Journal:  Med Decis Making       Date:  2001 Nov-Dec       Impact factor: 2.583

8.  Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Kristel Van Steen; Nele Esters; Sofie Joossens; Xavier Bossuyt; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

Review 9.  Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.

Authors:  Dianne C Berry; D K Raynor; Peter Knapp; Elisabetta Bersellini
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Authors:  Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

View more
  6 in total

Review 1.  Communicating genetic risk information for common disorders in the era of genomic medicine.

Authors:  Denise M Lautenbach; Kurt D Christensen; Jeffrey A Sparks; Robert C Green
Journal:  Annu Rev Genomics Hum Genet       Date:  2013       Impact factor: 8.929

Review 2.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

3.  Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.

Authors:  Christopher V Almario; Michelle S Keller; Michelle Chen; Karen Lasch; Lyann Ursos; Julia Shklovskaya; Gil Y Melmed; Brennan M R Spiegel
Journal:  Am J Gastroenterol       Date:  2017-12-05       Impact factor: 10.864

Review 4.  The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.

Authors:  Jessica Kimmel; Jordan Axelrad
Journal:  Curr Gastroenterol Rep       Date:  2020-02-13

Review 5.  Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice.

Authors:  Nikolaos Kyriakos; Apostolis Papaefthymiou; Marios Giakoumis; George Iatropoulos; Gerasimos Mantzaris; Christos Liatsos
Journal:  Ann Gastroenterol       Date:  2021-06-03

6.  Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study.

Authors:  James C Gregor; Martin Williamson; Dorota Dajnowiec; Bernie Sattin; Erik Sabot; Baljinder Salh
Journal:  Patient Prefer Adherence       Date:  2018-04-10       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.